Skip to main content
S&P 5007,688.62+1.58%DOW53,356.12+3.03%NASDAQ25,736.51+1.44%BTC$80,614.00+3.79%ETH$2,428.79+6.43%GOLD$4,072.900.00%OIL$88.19+0.08%
Smart Investors Daily
SID Premium
MB

NASDAQ · MBOT

Microbot Medical Inc.

Healthcare · Medical - Instruments & Supplies

$1.09

Up+$0.05 (+4.59%)

Updated Nov 4, 2026, 11:48 PM

SID Score

3.6/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
108.69M
P/E ratio
-12.46
Dividend yield
0.00%
52-week range
$0.93 – $2.86
Volume
1.21M
Avg. volume
3.35M

Price performance · MBOT

MBOT price history

1M range · 0 trading sessions · Daily adjusted prices

MBOT does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest MBOT news

The latest Smart Investors Daily articles mentioning MBOT.

Stock researchCompany · Overview

MBOT research

Overview

Company profile and research snapshot.

Company profile

Microbot Medical Inc is a breakthrough medical device company. The group is focused on transforming endovascular procedures through advanced robotic technology. Microbot's LIBERTY Endovascular Robotic System is the first single-use, remotely operated robotic solution designed for precision, efficiency and provider safety. With a robust intellectual property portfolio and a deep commitment to innovation, Microbot is shaping the future of endovascular care.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$5.50
Implied upside
—
Analysts
—
MBOT recent ratings
DateFirmRatingTarget
Oct 23, 2026CitizensMarket Outperform—
Oct 21, 2026HC Wainwright & Co.Buy—
Aug 14, 2026B. Riley SecuritiesBuy—
Jun 3, 2026LUCID CAPITAL MARKETSBuy—
Apr 14, 2026HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Mar 4, 2026

Microbot Medical® Aligns with Recently Adopted Policy of the Largest U.S.-Based Medical Association to Expand Protection for Healthcare Professionals from Ionizing Radiation

LIBERTY® Endovascular Robotic System’s Capability to Reduce Radiation Exposure Appeals to Hospitals and Healthcare ProvidersHINGHAM, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, commends the American Medical Association’s (AMA) expanding efforts to protect health care professionals from ionizing radiation. In late 2025, the AMA adopted a new policy to strengthen protections for he

Yahoo · Mar 3, 2026

Microbot Medical® Confirms Continued Operational and Commercial Stability Amid Current Geopolitical Event

HINGHAM, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced today that the Company, both in the USA and in Israel, is not experiencing any business disruption as a result of current geopolitical events. The safety and security of the employees remain its top priority. All personnel continue to operate as usual, and both internal operations and the lead manufacturing partner re

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By